CLL: Treatment and Management Strategies for Best Outcomes

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation.

Dr Linhares gives a comprehensive overview of tests a patient might expect to undergo at the time of diagnosis and why they are important.

Josie Montegaard, MSN, AGPCNP-BC, discusses the goals of treatment for patients with chronic lymphocytic leukemia and how they may vary depending on factors such as age, risk level, and symptoms.

Focusing on the first-line setting, Yuliya Linhares, MD, gives an overview of first-line treatment options for patients with chronic lymphocytic leukemia.

Dr Linhares provides clinical insights on factors that guide treatment decisions for patients with chronic lymphocytic leukemia, such as comorbidities and disease biology.

Josie Montegaard, MSN, AGPCNP-BC, offers expert perspectives on treatment considerations in CLL, focusing on BTK inhibitors and venetoclax-based therapy.

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Focusing on acalabrutinib-based treatment, Yuliya Linhares, MD, discusses results from the ELEVATE TN clinical trial.

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Expert perspectives on the SEQUOIA study, which is investigating zanubrutinib in patients with chronic lymphocytic leukemia.

Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.

Dr Linhares discusses newer combination therapies for the treatment of patients with chronic lymphocytic leukemia, highlighting ibrutinib and venetoclax, which is being studied in the CAPTIVATE trial.

Josie Montegaard, MSN, AGPCNP-BC, provides clinical insights on her approach to counseling patients who are receiving treatment for chronic lymphocytic leukemia.

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens.

A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.

Clinical insights on shared decision-making practices and the importance of supportive care when treating patients with chronic lymphocytic leukemia.

Yuliya Linhares, MD, discusses how healthy lifestyle choices, such as diet and exercise, can play a valuable role in optimizing CLL treatment outcomes.

Josie Montegaard, MSN, AGPCNP-BC, and Yuliya Linhares, MD, conclude their discussion with advice for patients with CLL on managing their diagnosis and treatment.